---
title: "Silexion Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286771797.md"
datetime: "2026-05-18T12:35:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286771797.md)
  - [en](https://longbridge.com/en/news/286771797.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286771797.md)
---

# Silexion Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.85.

EBIT: As of FY2026 Q1, the actual value is USD -2.749 M.

#### Operational Metrics

**Research and Development (R&D) Expenses**For the three months ended March 31, 2026, R&D expenses were $1,370 thousand, an increase of 133.3% from $590 thousand for the same period in 2025. This increase was primarily due to approximately $700 thousand in higher subcontractor and consultant expenses related to toxicology studies, product development, and GMP manufacturing, as well as approximately $100 thousand in non-cash share-based compensation expenses .

**General and Administrative (G&A) Expenses**G&A expenses for the three months ended March 31, 2026, were $1,379 thousand, up 27.3% from $1,060 thousand in the prior-year period. This rise was mainly driven by approximately $260 thousand in higher professional services costs and approximately $200 thousand in non-cash share-based compensation expenses .

**Total Operating Expenses**Total operating expenses for the three months ended March 31, 2026, were $2,749 thousand, compared to $1,650 thousand for the same period in 2025 .

**Operating Loss**The operating loss was - $2,749 thousand for the three months ended March 31, 2026, compared to an operating loss of - $1,650 thousand for the same period in 2025 .

**Financial Expense (Income), Net**Net financial income was - $16 thousand for the three months ended March 31, 2026, compared to a financial expense of $85 thousand for the same period in 2025 .

**Net Loss**Silexion Therapeutics Corp reported a net loss of - $2,733 thousand for the three months ended March 31, 2026, an increase of 58.8% from the net loss of - $1,735 thousand for the same period in 2025. This increase was primarily attributed to higher research and development expenses and general and administrative expenses .

**Loss Per Share, Basic and Diluted**Loss per share, basic and diluted, was - $0.85 for the three months ended March 31, 2026, compared to - $3.84 for the same period in 2025 .

#### Cash and Balance Sheet Metrics

**Cash and Cash Equivalents**Cash and cash equivalents decreased to $2,413 thousand as of March 31, 2026, from $5,991 thousand as of December 31, 2025. This decrease primarily reflects ongoing operating expenses supporting preclinical and clinical readiness activities .

**Total Assets**Total assets were $4,602 thousand as of March 31, 2026, down from $7,215 thousand as of December 31, 2025 .

**Total Liabilities**Total liabilities were $4,311 thousand as of March 31, 2026, compared to $4,612 thousand as of December 31, 2025 .

**Total Shareholders’ Equity (Capital Deficiency)**Total shareholders’ equity was $291 thousand as of March 31, 2026, a decrease from $2,603 thousand as of December 31, 2025 .

#### Unique Metrics

**Subsequent Capital Raising and Nasdaq Compliance**Subsequent to the quarter end, Silexion Therapeutics Corp generated approximately $1.0 million in gross proceeds from a May 2026 warrant exercise inducement transaction and through its at-the-market facility . The company anticipates these transactions, along with additional equity-increasing activities, have raised its shareholders’ equity above the $2.5 million minimum required for continued listing on the Nasdaq Capital Market, thereby restoring compliance .

#### Outlook / Guidance

Silexion Therapeutics Corp expects to initiate its Phase 2⁄3 clinical trial for SIL204 in locally advanced pancreatic cancer in the second quarter of 2026. This trial will begin with an initial safety run-in cohort of approximately 18 patients, followed by an expansion into a randomized cohort of about 166 patients. The company is actively exploring financing options to support the clinical advancement of SIL204 .

### Related Stocks

- [SLXN.US](https://longbridge.com/en/quote/SLXN.US.md)

## Related News & Research

- [PowerFleet Q4 2026 Earnings Preview](https://longbridge.com/en/news/289616465.md)
- [ABB  Ltd: ABB share buybacks - June 4, 2026 – June 10, 2026](https://longbridge.com/en/news/289436946.md)
- [Soybean Analysis: 2026 Market Volatility and Trend](https://longbridge.com/en/news/289444628.md)
- [Zedge Q3 2026 Earnings Preview](https://longbridge.com/en/news/289381005.md)
- [8 big takeaways from Apple's WWDC 2026 event](https://longbridge.com/en/news/289107553.md)